On December 1, the US Food and Drug Administration (FDA) issued a spate of warning letters to drug and biologic manufacturers for marketing unapproved products.
All three letter recipients – BioXtek, Celularity, and Lux Therapeutics – are manufacturers that utilize human cells, tissues, and cellular and tissue-based products (HCT/Ps) in the
Each
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
